Sandbox/AL: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 9: Line 9:
! style="background: #4479BA; color:#FFF;  width: 350px;" | Treatment
! style="background: #4479BA; color:#FFF;  width: 350px;" | Treatment
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Pneumocystis pneumonia|Pneumocystis Pneumonia]] <br> <br><small>[[HIV opportunistic infection pneumocystis pneumonia: prevention and treatment guidelines|(Click here for more information])]</small>
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Pneumocystis pneumonia|Pneumocystis Pneumonia]] <br> <br><small>[[HIV opportunistic infection pneumocystis pneumonia: prevention and treatment guidelines|(Click here for more information)]]</small>
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Caused by the fungus ''Pneumocystis jirovecii''.  
*Caused by the fungus ''Pneumocystis jirovecii''.  
Line 21: Line 21:
*<small>Administer adjunctive corticosteroids in patients with pO2 <70 mm Hg or arterial-alveolar O2 gradient >35 mm Hg</small>
*<small>Administer adjunctive corticosteroids in patients with pO2 <70 mm Hg or arterial-alveolar O2 gradient >35 mm Hg</small>
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Toxoplasma gondii]] Encephalitis<br> <br><small>[[HIV opportunistic infection toxoplasma gondii encephalitis: prevention and treatment guidelines|(Click here for more information])]</small>
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | [[Toxoplasma gondii]] Encephalitis<br> <br><small>[[HIV opportunistic infection toxoplasma gondii encephalitis: prevention and treatment guidelines|(Click here for more information)]]</small>
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Caused by the protozoan ''Toxoplasma gondii''
* Caused by the protozoan ''Toxoplasma gondii''

Revision as of 20:25, 14 October 2014

Disease Description Clinical Findings Diagnosis Prophylaxis Treatment
Pneumocystis Pneumonia

(Click here for more information)
  • Caused by the fungus Pneumocystis jirovecii.
  • 90% of cases occurred among patients with CD4+ <200
  • Incidence among HIV patients: 2-3 cases per 100 person-year
Subacute onset of progressive dyspnea, fever, nonproductive cough, and chest discomfort that worsens within days to weeks. Tachypnea, tachycardia, and diffuse dry rales are found in the physical examination. Clinical presentation, blood tests, or chest x-rays are not pathognomonic for PCP. Start TMP-SMX prophylaxis when CD4+ <200 cells/µL or history of oropharyngeal candidiasis.
Discontinue prophylaxis when CD4+ is >200 cells/µL for >3 month.
  • TMP-SMX
  • Administer adjunctive corticosteroids in patients with pO2 <70 mm Hg or arterial-alveolar O2 gradient >35 mm Hg
Toxoplasma gondii Encephalitis

(Click here for more information)
  • Caused by the protozoan Toxoplasma gondii
  • The greatest risk of disease occurs among patients with a CD4+ <50 cells/µL
  • Primary infection occurs after eating undercooked meat containing tissue cysts or ingesting oocysts that have been shed in cat feces and have sporulated in the environment
Focal encephalitis with headache, confusion, or motor weakness and fever Diagnosis is done with IgG antibodies. CT scan or MRI of the brain will typically show multiple contrast-enhancing lesions, often with associated edema. Definite diagnosis requires a brain biopsy. Start TMP-SMX prophylaxis when CD4+ <100 cells/µL
Discontinue prophylaxis when CD4+ is >200 cells/µL for >3 month.
Administer:
Cryptosporidiosis
Microsporidiosis
Mycobacterium tuberculosis
Table adapted from Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents [1]
  1. "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents".